ArticleFrontiers in oncology2024

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Anna Brandt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.